血清miR-22-3p、CYR61水平对乳腺癌诊断及复发转移预测的临床价值  

Value of serum miR-22-3p and CYR61 levels in diagnosis of breast cancer and their prediction on recurrence and metastasis

作　　者：喻珊珊 喻茂文 谭辉 YU Shanshan;YU Maowen;TAN Hui(The Third Department of Internal Medicine,Cancer Hospital Affiliated to Shantou University Medical School,Shantou China;不详)

机构地区：[1]汕头大学医学院附属肿瘤医院内三科,广东汕头515041 [2]四川大学华西医院金堂医院实验医学科 [3]成都同昌医学检验所有限公司

出　　处：《山东医药》2024年第16期1-5,共5页Shandong Medical Journal

基　　金：国家重点基础研究发展计划(973计划)子课题(2015CB755402_108)。

摘　　要：目的探讨血清微小RNA-22-3p(miR-22-3p)、富含半胱氨酸蛋白61(CYR61)水平对乳腺癌诊断及复发转移预测的临床价值。方法选择乳腺癌患者110例(观察组),接受改良根治术后随访1年,发生复发转移25例、未发生复发转移85例,同期选择乳腺良性疾病患者110例(对照组),采集所有研究对象外周静脉血,离心留取血清,采用RT-qPCR法检测血清miR-22-3p、采用ELISA法检测血清CYR61。比较观察组与对照组、复发转移者与未复发转移者血清miR-22-3p、CYR61水平,采用受试者工作特征(ROC)曲线分析血清miR-22-3p、CYR61水平对乳腺癌诊断及复发转移预测的临床价值。采用Pearson相关分析法分析乳腺癌患者血清miR-22-3p水平与血清CYR61水平的关系。结果观察组与对照组血清miR-22-3p水平分别为0.65±0.14、1.02±0.23,血清CYR61水平分别为(128.63±25.72)、(96.45±17.31)μg/L。观察组血清miR-22-3p水平低于对照组,血清CYR61水平高于对照组(t分别为14.802、10.886,P均<0.01)。ROC曲线分析显示,血清miR-22-3p、CYR61水平单独及联合诊断乳腺癌的曲线下面积(AUC)分别为0.917、0.857、0.960,血清miR-22-3p、CYR61水平联合诊断乳腺癌的AUC高于二者单独(Z分别为3.321、4.512,P均<0.05)。乳腺癌复发转移者与未复发转移者血清miR-22-3p水平分别为0.45±0.12、0.71±0.24,血清CYR61水平分别为(162.94±29.78)、(118.53±25.49)μg/L。乳腺癌复发转移者血清miR-22-3p水平低于未复发转移者,血清CYR61水平高于未复发转移者(t分别为5.216、7.365,P均<0.01)。血清miR-22-3p、CYR61水平单独及联合预测乳腺癌复发转移的AUC分别为0.838、0.831、0.932,血清miR-22-3p、CYR61水平联合预测乳腺癌复发转移的AUC高于二者单独(Z分别为2.493、2.196,P均<0.05)。Pearson相关分析显示,乳腺癌患者血清miR-22-3p水平与血清CYR61水平呈负相关关系(r=-0.643,P<0.05)。结论血清miR-22-3p、CYR61水平对乳腺癌诊断及复发转移预测均�Objective To investigate the diagnostic value of serum microRNA-22-3p(miR-22-3p)and cysteine-rich protein 61(CYR61)levels in breast cancer and their prediction on recurrence and metastasis.Methods Totally 110 patients with breast cancer(observation group)receiving improved radical surgery were selected and followed up for 1 year;there were 25 patients with recurrence and metastasis and 85 patients without recurrence and metastasis.Mean-while,110 patients with benign breast diseases(control group)were selected during the same period.Peripheral venous blood of all subjects was collected and serum was retained by centrifugation.Serum miR-22-3p was detected by RT-qPCR and serum CYR61 was detected by ELISA.Serum miR-22-3p and CYR61 levels were compared between the observation group and the control group,and between patients with recurrence and metastasis and those without recurrence and metas-tasis.The value of serum miR-22-3p and CYR61 levels in diagnosis of breast cancer and their predictive value on recur-rence and metastasis were analyzed by receiver operating characteristic(ROC)curve.Pearson correlation analysis was used to analyze the relationship between serum miR-22-3p level and serum CYR61 level in breast cancer patients.Results The levels of miR-22-3p in the observation group and control group were 0.65±0.14 and 1.02±0.23,respec-tively,and the levels of CYR61 in the serum were(128.63±25.72)and(96.45±17.31)μg/L,respectively.The serum miR-22-3p level in the observation group was lower than that in the control group,and the serum CYR61 level was higher than that in the control group(t=14.802 and 10.886,respectively,both P<0.01).ROC curve analysis showed that the area under the curve(AUC)of serum miR-22-3p and CYR61 levels in the diagnosis of breast cancer alone and combined were 0.917,0.857 and 0.960,respectively.The AUC of serum miR-22-3p combined with CYR61 levels in the diagnosis of breast cancer was higher than that of either alone(Z=3.321 and 4.512,respectively,both P<0.05).Serum miR-22-3p levels were

关 键 词：乳腺癌 微小RNA-22-3p 富含半胱氨酸蛋白61 复发转移 

分 类 号：R737.9[医药卫生—肿瘤]